메뉴 건너뛰기




Volumn 13, Issue 1, 2015, Pages 1-21

Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: How similar, how different, and how to treat?

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ABSORPTION INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

EID: 84921501320     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2014.0049     Document Type: Review
Times cited : (27)

References (172)
  • 1
    • 65349195631 scopus 로고    scopus 로고
    • The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus
    • Ginsberg HN, MacCallum PR, Henry N. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113-119.
    • (2009) J Cardiometab Syndr , vol.4 , pp. 113-119
    • Ginsberg, H.N.1    MacCallum, P.R.2    Henry, N.3
  • 2
    • 74049143053 scopus 로고    scopus 로고
    • Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure
    • Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010;55:283-293.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 283-293
    • Horwich, T.B.1    Fonarow, G.C.2
  • 3
    • 44649098307 scopus 로고    scopus 로고
    • Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
    • Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-822.
    • (2008) Diabetes Care , vol.31 , pp. 811-822
    • Brunzell, J.D.1    Davidson, M.2    Furberg, C.D.3
  • 4
    • 79960539641 scopus 로고    scopus 로고
    • ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)
    • Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-1818.
    • (2011) Eur Heart J , vol.32 , pp. 1769-1818
    • Reiner, Z.1    Catapano, A.L.2    De Backer, G.3
  • 5
    • 78650223573 scopus 로고    scopus 로고
    • Atherogenic dyslipidemia: Cardiovascular risk and dietary intervention
    • Musunuru K. Atherogenic dyslipidemia: Cardiovascular risk and dietary intervention. Lipids 2010;45:907-914.
    • (2010) Lipids , vol.45 , pp. 907-914
    • Musunuru, K.1
  • 8
    • 79955562491 scopus 로고    scopus 로고
    • Metabolic syndrome: Definitions and controversies
    • Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: Definitions and controversies. BMC Med 2011;9:48.
    • (2011) BMC Med , vol.9 , pp. 48
    • Kassi, E.1    Pervanidou, P.2    Kaltsas, G.3
  • 9
    • 33846422032 scopus 로고    scopus 로고
    • Obesity and diabetes in the developing world-A growing challenge
    • Hossain P, Kawar B, El NM. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007;356:213-215.
    • (2007) N Engl J Med , vol.356 , pp. 213-215
    • Hossain, P.1    Kawar, B.2    El, N.M.3
  • 10
    • 55849137212 scopus 로고    scopus 로고
    • Obesity and the metabolic syndrome in developing countries
    • Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008;93(Suppl 1):S9-S30.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. S9-S30
    • Misra, A.1    Khurana, L.2
  • 11
    • 84880375219 scopus 로고    scopus 로고
    • Obesity and dyslipidemia in South Asians
    • Misra A, Shrivastava U. Obesity and dyslipidemia in South Asians. Nutrients 2013;5:2708-2733.
    • (2013) Nutrients , vol.5 , pp. 2708-2733
    • Misra, A.1    Shrivastava, U.2
  • 12
    • 79960202841 scopus 로고    scopus 로고
    • Type 2 diabetes across generations: From pathophysiology to prevention and management
    • Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet 2011;378:169-181.
    • (2011) Lancet , vol.378 , pp. 169-181
    • Nolan, C.J.1    Damm, P.2    Prentki, M.3
  • 13
    • 75149180515 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2010
    • American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1): S11-S61.
    • (2010) Diabetes Care , vol.33 , pp. S11-S61
  • 14
    • 79955634896 scopus 로고    scopus 로고
    • Abbreviated report of a World Health Organization (WHO) consultation
    • World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a World Health Organization (WHO) consultation. 2013. Available at http://whoint/diabetes/publications/report-hba1c-2011pdf
    • (2013) Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus
  • 16
    • 84862302432 scopus 로고    scopus 로고
    • Prediabetes: A high-risk state for diabetes development
    • Tabak AG, Herder C, Rathmann W, et al. Prediabetes: A high-risk state for diabetes development. Lancet 2012;379: 2279-2290.
    • (2012) Lancet , vol.379 , pp. 2279-2290
    • Tabak, A.G.1    Herder, C.2    Rathmann, W.3
  • 17
    • 0024160877 scopus 로고
    • Banting lecture 1988. Role of insulin resistance in human disease
    • Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
    • (1988) Diabetes , vol.37 , pp. 1595-1607
    • Reaven, G.M.1
  • 18
    • 24144484876 scopus 로고    scopus 로고
    • The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
    • Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
    • (2005) Diabetes Care , vol.28 , pp. 2289-2304
    • Kahn, R.1    Buse, J.2    Ferrannini, E.3
  • 19
    • 34247193564 scopus 로고    scopus 로고
    • Metabolic syndrome: Is it a syndrome? Does it matter?
    • Kahn R. Metabolic syndrome: Is it a syndrome? Does it matter? Circulation 2007;115:1806-1810.
    • (2007) Circulation , vol.115 , pp. 1806-1810
    • Kahn, R.1
  • 20
    • 0032510639 scopus 로고    scopus 로고
    • Prediction of coronary heart disease using risk factor categories
    • Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
    • (1998) Circulation , vol.97 , pp. 1837-1847
    • Wilson, P.W.1    D'Agostino, R.B.2    Levy, D.3
  • 21
    • 70350245011 scopus 로고    scopus 로고
    • Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity
    • Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
    • (2009) Circulation , vol.120 , pp. 1640-1645
    • Alberti, K.G.1    Eckel, R.H.2    Grundy, S.M.3
  • 22
    • 33644872972 scopus 로고    scopus 로고
    • Familial hypercholesterolemia: A challenge of diagnosis and therapy
    • Sibley C, Stone NJ. Familial hypercholesterolemia: A challenge of diagnosis and therapy. Cleve Clin J Med 2006; 73:57-64.
    • (2006) Cleve Clin J Med , vol.73 , pp. 57-64
    • Sibley, C.1    Stone, N.J.2
  • 23
    • 79957977001 scopus 로고    scopus 로고
    • Array-based resequencing for mutations causing familial hypercholesterolemia
    • Chiou KR, Charng MJ, Chang HM. Array-based resequencing for mutations causing familial hypercholesterolemia. Atherosclerosis 2011;216:383-389.
    • (2011) Atherosclerosis , vol.216 , pp. 383-389
    • Chiou, K.R.1    Charng, M.J.2    Chang, H.M.3
  • 24
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 25
    • 43249113169 scopus 로고    scopus 로고
    • Familial combined hyperlipidaemia: Under-defined and underdiagnosed?
    • Wierzbicki AS, Graham CA, Young IS, et al. Familial combined hyperlipidaemia: Under-defined and underdiagnosed? Curr Vasc Pharmacol 2008;6:13-22.
    • (2008) Curr Vasc Pharmacol , vol.6 , pp. 13-22
    • Wierzbicki, A.S.1    Graham, C.A.2    Young, I.S.3
  • 27
    • 84860235809 scopus 로고    scopus 로고
    • Association of alcohol consumption with lipid profile in hypertensive men
    • Park H, Kim K. Association of alcohol consumption with lipid profile in hypertensive men. Alcohol Alcohol 2012;47:282-287.
    • (2012) Alcohol Alcohol , vol.47 , pp. 282-287
    • Park, H.1    Kim, K.2
  • 28
    • 79955430659 scopus 로고    scopus 로고
    • Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus
    • Wakabayashi I. Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus. Alcohol Alcohol 2011;46: 301-307.
    • (2011) Alcohol Alcohol , vol.46 , pp. 301-307
    • Wakabayashi, I.1
  • 29
    • 0036070865 scopus 로고    scopus 로고
    • Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis
    • Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002;51:265-269.
    • (2002) Gut , vol.51 , pp. 265-269
    • Longo, M.1    Crosignani, A.2    Battezzati, P.M.3
  • 30
    • 0026031716 scopus 로고
    • Lipid abnormalities in renal disease
    • Appel G. Lipid abnormalities in renal disease. Kidney Int 1991;39:169-183.
    • (1991) Kidney Int , vol.39 , pp. 169-183
    • Appel, G.1
  • 31
    • 0027319164 scopus 로고
    • The nephrotic syndrome, lipids, and risk factors for cardiovascular disease
    • Radhakrishnan J, Appel AS, Valeri A, et al. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993;22:135-142.
    • (1993) Am J Kidney Dis , vol.22 , pp. 135-142
    • Radhakrishnan, J.1    Appel, A.S.2    Valeri, A.3
  • 32
    • 0028288403 scopus 로고
    • Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment
    • Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis 1994;23:331-346.
    • (1994) Am J Kidney Dis , vol.23 , pp. 331-346
    • Wheeler, D.C.1    Bernard, D.B.2
  • 33
    • 0027162504 scopus 로고
    • Hyperlipidemia in patients with primary and secondary hypothyroidism
    • O'Brien T, Dinneen SF, O'Brien PC, et al. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993;68:860-866.
    • (1993) Mayo Clin Proc , vol.68 , pp. 860-866
    • O'Brien, T.1    Dinneen, S.F.2    O'Brien, P.C.3
  • 34
    • 0033397395 scopus 로고    scopus 로고
    • The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study
    • Dursun SM, Szemis A, Andrews H, et al. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study. J Psychiatry Neurosci 1999;24:453-455.
    • (1999) J Psychiatry Neurosci , vol.24 , pp. 453-455
    • Dursun, S.M.1    Szemis, A.2    Andrews, H.3
  • 35
    • 0028896514 scopus 로고
    • Effects of antihypertensive therapy on serum lipids
    • Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-141.
    • (1995) Ann Intern Med , vol.122 , pp. 133-141
    • Kasiske, B.L.1    Ma, J.Z.2    Kalil, R.S.3
  • 36
    • 84864131448 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel
    • Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
    • (2012) JAMA , vol.308 , pp. 387-402
    • Thompson, M.A.1    Aberg, J.A.2    Hoy, J.F.3
  • 38
    • 0031014495 scopus 로고    scopus 로고
    • Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
    • Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
    • (1997) Circulation , vol.95 , pp. 1-4
    • Grundy, S.M.1
  • 39
    • 0031935662 scopus 로고    scopus 로고
    • An overview of reverse cholesterol transport
    • Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998;19(Suppl A):A31-A35.
    • (1998) Eur Heart J , vol.19 , pp. A31-A35
    • Tall, A.R.1
  • 40
    • 0024501678 scopus 로고
    • Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
    • Gordon DJ, Probstfield JL, Garrison RJ, et al. Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79: 8-15.
    • (1989) Circulation , vol.79 , pp. 8-15
    • Gordon, D.J.1    Probstfield, J.L.2    Garrison, R.J.3
  • 41
    • 34748887666 scopus 로고    scopus 로고
    • HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    • Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310.
    • (2007) N Engl J Med , vol.357 , pp. 1301-1310
    • Barter, P.1    Gotto, A.M.2    Larosa, J.C.3
  • 42
    • 85027956925 scopus 로고    scopus 로고
    • Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association
    • Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011;123:2292-2333.
    • (2011) Circulation , vol.123 , pp. 2292-2333
    • Miller, M.1    Stone, N.J.2    Ballantyne, C.3
  • 43
    • 84893127732 scopus 로고    scopus 로고
    • Assessing the clinical benefits of lipid-disorder drugs
    • Hiatt WR, Smith RJ. Assessing the clinical benefits of lipid-disorder drugs. N Engl J Med 2014;370:396-399.
    • (2014) N Engl J Med , vol.370 , pp. 396-399
    • Hiatt, W.R.1    Smith, R.J.2
  • 45
    • 81255137973 scopus 로고    scopus 로고
    • The role of triglycerides in atherosclerosis
    • Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011;13:544-552.
    • (2011) Curr Cardiol Rep , vol.13 , pp. 544-552
    • Talayero, B.G.1    Sacks, F.M.2
  • 46
    • 0031032723 scopus 로고    scopus 로고
    • Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
    • Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95: 69-75.
    • (1997) Circulation , vol.95 , pp. 69-75
    • Lamarche, B.1    Tchernof, A.2    Moorjani, S.3
  • 47
    • 82955247909 scopus 로고    scopus 로고
    • IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
    • Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321.
    • (2011) Diabetes Res Clin Pract , vol.94 , pp. 311-321
    • Whiting, D.R.1    Guariguata, L.2    Weil, C.3
  • 48
    • 2342466734 scopus 로고    scopus 로고
    • Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030
    • Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
    • (2004) Diabetes Care , vol.27 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3
  • 49
    • 3142735789 scopus 로고    scopus 로고
    • The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up
    • Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-1426.
    • (2004) Arch Intern Med , vol.164 , pp. 1422-1426
    • Almdal, T.1    Scharling, H.2    Jensen, J.S.3
  • 50
    • 0042671239 scopus 로고    scopus 로고
    • Cardiovascular disease and diabetes
    • Bloomgarden ZT. Cardiovascular disease and diabetes. Diabetes Care 2003;26:230-237.
    • (2003) Diabetes Care , vol.26 , pp. 230-237
    • Bloomgarden, Z.T.1
  • 51
    • 0032560807 scopus 로고    scopus 로고
    • Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
    • Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
    • (1998) N Engl J Med , vol.339 , pp. 229-234
    • Haffner, S.M.1    Lehto, S.2    Ronnemaa, T.3
  • 52
    • 0037407403 scopus 로고    scopus 로고
    • NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
    • Alexander CM, Landsman PB, Teutsch SM, et al. NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-1214.
    • (2003) Diabetes , vol.52 , pp. 1210-1214
    • Alexander, C.M.1    Landsman, P.B.2    Teutsch, S.M.3
  • 53
    • 58849101669 scopus 로고    scopus 로고
    • Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes
    • Zoppini G, Targher G, Trombetta M, et al. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. Obesity (Silver Spring) 2009;17:370-374.
    • (2009) Obesity (Silver Spring) , vol.17 , pp. 370-374
    • Zoppini, G.1    Targher, G.2    Trombetta, M.3
  • 54
    • 84866738927 scopus 로고    scopus 로고
    • Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoproteincholesterol levels
    • Querton L, Buysschaert M, Hermans MP. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoproteincholesterol levels. J Clin Lipidol 2012;6:434-442.
    • (2012) J Clin Lipidol , vol.6 , pp. 434-442
    • Querton, L.1    Buysschaert, M.2    Hermans, M.P.3
  • 55
    • 84873868818 scopus 로고    scopus 로고
    • Joint prevalence of diabetes, impaired glucose regulation, cardiovascular disease risk and chronic kidney disease in South Asians and White Europeans
    • Khunti K, Morris DH, Weston CL, et al. Joint prevalence of diabetes, impaired glucose regulation, cardiovascular disease risk and chronic kidney disease in South Asians and White Europeans. PLoS One 2013;8:e55580.
    • (2013) PLoS One , vol.8 , pp. e55580
    • Khunti, K.1    Morris, D.H.2    Weston, C.L.3
  • 57
    • 33845984333 scopus 로고    scopus 로고
    • Epidemic obesity and type 2 diabetes in Asia
    • Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-1688.
    • (2006) Lancet , vol.368 , pp. 1681-1688
    • Yoon, K.H.1    Lee, J.H.2    Kim, J.W.3
  • 58
    • 34249297625 scopus 로고    scopus 로고
    • The metabolic syndrome in South Asians: Continuing escalation & possible solutions
    • Misra A, Misra R, Wijesuriya M, et al. The metabolic syndrome in South Asians: Continuing escalation & possible solutions. Indian J Med Res 2007;125:345-354.
    • (2007) Indian J Med Res , vol.125 , pp. 345-354
    • Misra, A.1    Misra, R.2    Wijesuriya, M.3
  • 59
    • 44649143714 scopus 로고    scopus 로고
    • High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India
    • Ramachandran A, Mary S, Yamuna A, et al. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008;31: 893-898.
    • (2008) Diabetes Care , vol.31 , pp. 893-898
    • Ramachandran, A.1    Mary, S.2    Yamuna, A.3
  • 60
    • 0027448688 scopus 로고
    • DNA polymorphisms of the apolipoprotein B gene are associated with obesity and serum lipids in healthy Indians in Singapore
    • Saha N, Tay JS, Heng CK, et al. DNA polymorphisms of the apolipoprotein B gene are associated with obesity and serum lipids in healthy Indians in Singapore. Clin Genet 1993;44:113-120.
    • (1993) Clin Genet , vol.44 , pp. 113-120
    • Saha, N.1    Tay, J.S.2    Heng, C.K.3
  • 61
    • 20444493880 scopus 로고    scopus 로고
    • Insights from the developing world: Thrifty genotypes and thrifty phenotypes
    • Prentice AM, Rayco-Solon P, Moore SE. Insights from the developing world: Thrifty genotypes and thrifty phenotypes. Proc Nutr Soc 2005;64:153-161.
    • (2005) Proc Nutr Soc , vol.64 , pp. 153-161
    • Prentice, A.M.1    Rayco-Solon, P.2    Moore, S.E.3
  • 62
    • 32144455202 scopus 로고    scopus 로고
    • The emerging epidemic of obesity in developing countries
    • Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006;35:93-99.
    • (2006) Int J Epidemiol , vol.35 , pp. 93-99
    • Prentice, A.M.1
  • 63
    • 34248652104 scopus 로고    scopus 로고
    • Search for genetic factors predisposing to atherogenic dyslipidemia
    • Yip AG, Ma Q, Wilcox M, et al. Search for genetic factors predisposing to atherogenic dyslipidemia. BMC Genet 2003;4(Suppl 1):S100.
    • (2003) BMC Genet , vol.4 , pp. S100
    • Yip, A.G.1    Ma, Q.2    Wilcox, M.3
  • 64
    • 78649664457 scopus 로고    scopus 로고
    • Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany
    • Gitt AK, Junger C, Smolka W, et al. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol 2010;99:723-733.
    • (2010) Clin Res Cardiol , vol.99 , pp. 723-733
    • Gitt, A.K.1    Junger, C.2    Smolka, W.3
  • 65
    • 27544487525 scopus 로고    scopus 로고
    • Prevalence and control of dyslipidemia among persons with diabetes in the United States
    • Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005;70:263-269.
    • (2005) Diabetes Res Clin Pract , vol.70 , pp. 263-269
    • Jacobs, M.J.1    Kleisli, T.2    Pio, J.R.3
  • 66
    • 0027406191 scopus 로고
    • Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
    • Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
    • (1993) Diabetes Care , vol.16 , pp. 434-444
    • Stamler, J.1    Vaccaro, O.2    Neaton, J.D.3
  • 67
    • 11844278418 scopus 로고    scopus 로고
    • Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?
    • Drexel H, Aczel S, Marte T, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005;28:101-107.
    • (2005) Diabetes Care , vol.28 , pp. 101-107
    • Drexel, H.1    Aczel, S.2    Marte, T.3
  • 68
    • 80051769525 scopus 로고    scopus 로고
    • European panel on low density lipoprotein (LDL) subclasses: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: Executive summary
    • Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011;9:531-532.
    • (2011) Curr Vasc Pharmacol , vol.9 , pp. 531-532
    • Mikhailidis, D.P.1    Elisaf, M.2    Rizzo, M.3
  • 69
    • 19944397142 scopus 로고    scopus 로고
    • Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study
    • Sone H, Mizuno S, Fujii H, et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005;28:1463-1471.
    • (2005) Diabetes Care , vol.28 , pp. 1463-1471
    • Sone, H.1    Mizuno, S.2    Fujii, H.3
  • 70
    • 13744254491 scopus 로고    scopus 로고
    • Dyslipidemia in Asian Indians: Determinants and significance
    • Misra A, Luthra K, Vikram NK. Dyslipidemia in Asian Indians: Determinants and significance. J Assoc Physicians India 2004;52:137-142.
    • (2004) J Assoc Physicians India , vol.52 , pp. 137-142
    • Misra, A.1    Luthra, K.2    Vikram, N.K.3
  • 72
    • 79959272069 scopus 로고    scopus 로고
    • Cholesterol ester transfer protein and apolipoprotein e gene polymorphisms in hyperlipidemic Asian Indians in North India
    • Meena K, Misra A, Vikram N, et al. Cholesterol ester transfer protein and apolipoprotein E gene polymorphisms in hyperlipidemic Asian Indians in North India. Mol Cell Biochem 2011;352:189-196.
    • (2011) Mol Cell Biochem , vol.352 , pp. 189-196
    • Meena, K.1    Misra, A.2    Vikram, N.3
  • 73
    • 84865276881 scopus 로고    scopus 로고
    • Association of the myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in North India
    • Bhatt SP, Nigam P, Misra A, et al. Association of the myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in North India. PLoS One 2012;7:e40977.
    • (2012) PLoS One , vol.7 , pp. e40977
    • Bhatt, S.P.1    Nigam, P.2    Misra, A.3
  • 74
    • 58849121390 scopus 로고    scopus 로고
    • Apolipoprotein e gene polymorphism and dyslipidaemia in adult Asian Indians: A population based study from Calcutta, India
    • Das M, Pal S, Ghosh A. Apolipoprotein E gene polymorphism and dyslipidaemia in adult Asian Indians: A population based study from Calcutta, India. Indian J Hum Genet 2008;14:87-91.
    • (2008) Indian J Hum Genet , vol.14 , pp. 87-91
    • Das, M.1    Pal, S.2    Ghosh, A.3
  • 75
    • 84892729932 scopus 로고    scopus 로고
    • Assessment of 11-beta hydroxysteroid dehydrogenase (11-betaHSD1) 4478T→G and tumor necrosis factor-alpha (TNF-alpha)- 308G→A polymorphisms with obesity and insulin resistance in Asian Indians in North India
    • [Epub ahead of print]
    • Sharma M, Vikram NK, Misra A, et al. Assessment of 11-beta hydroxysteroid dehydrogenase (11-betaHSD1) 4478T→G and tumor necrosis factor-alpha (TNF-alpha)- 308G→A polymorphisms with obesity and insulin resistance in Asian Indians in North India. Mol Biol Rep 2013;[Epub ahead of print].
    • (2013) Mol Biol Rep
    • Sharma, M.1    Vikram, N.K.2    Misra, A.3
  • 76
    • 32544443164 scopus 로고    scopus 로고
    • Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia
    • Ginsberg HN. Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006;91:383-392.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 383-392
    • Ginsberg, H.N.1
  • 77
    • 70350066787 scopus 로고    scopus 로고
    • The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia
    • Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. J Clin Hypertens (Greenwich) 2009;11:520-527.
    • (2009) J Clin Hypertens (Greenwich) , vol.11 , pp. 520-527
    • Ginsberg, H.N.1    MacCallum, P.R.2
  • 78
    • 48349134171 scopus 로고    scopus 로고
    • Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit
    • McTaggart F, Jones P. Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008;22:321-338.
    • (2008) Cardiovasc Drugs Ther , vol.22 , pp. 321-338
    • McTaggart, F.1    Jones, P.2
  • 79
    • 0035910051 scopus 로고    scopus 로고
    • Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
    • Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051.
    • (2001) Circulation , vol.104 , pp. 3046-3051
    • Ballantyne, C.M.1    Olsson, A.G.2    Cook, T.J.3
  • 80
    • 0034604225 scopus 로고    scopus 로고
    • Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
    • BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27.
    • (2000) Circulation , vol.102 , pp. 21-27
  • 81
    • 33646829645 scopus 로고    scopus 로고
    • Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials
    • Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ 2006;332:1115-1124.
    • (2006) BMJ , vol.332 , pp. 1115-1124
    • Costa, J.1    Borges, M.2    David, C.3
  • 82
    • 33748303084 scopus 로고    scopus 로고
    • Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study
    • Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 2006;368:919-928.
    • (2006) Lancet , vol.368 , pp. 919-928
    • Deedwania, P.1    Barter, P.2    Carmena, R.3
  • 83
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
    • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 84
    • 0023232216 scopus 로고
    • Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
    • (1987) N Engl J Med , vol.317 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3
  • 85
    • 26444447495 scopus 로고    scopus 로고
    • Impact of statins in microalbuminuric subjects with the metabolic syndrome: A substudy of the PREVEND Intervention Trial
    • Geluk CA, Asselbergs FW, Hillege HL, et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: A substudy of the PREVEND Intervention Trial. Eur Heart J 2005;26:1314-1320.
    • (2005) Eur Heart J , vol.26 , pp. 1314-1320
    • Geluk, C.A.1    Asselbergs, F.W.2    Hillege, H.L.3
  • 86
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
    • (2010) N Engl J Med , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 87
    • 28044452217 scopus 로고    scopus 로고
    • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
    • Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-1861
    • (2005) Lancet , vol.366 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 88
    • 33750159238 scopus 로고    scopus 로고
    • Erratum in: Lancet 2006;368:1415
    • (2006) Lancet , vol.368 , pp. 1415
  • 89
    • 79960700766 scopus 로고    scopus 로고
    • Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
    • Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis 2011;217: 492-498.
    • (2011) Atherosclerosis , vol.217 , pp. 492-498
    • Lee, M.1    Saver, J.L.2    Towfighi, A.3
  • 90
    • 0026597808 scopus 로고
    • Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
    • Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
    • (1992) Circulation , vol.85 , pp. 37-45
    • Manninen, V.1    Tenkanen, L.2    Koskinen, P.3
  • 91
    • 0033527030 scopus 로고    scopus 로고
    • Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
    • Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341: 410-418.
    • (1999) N Engl J Med , vol.341 , pp. 410-418
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3
  • 92
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): A multicentre randomised controlled trial
    • Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
    • (2003) Lancet , vol.361 , pp. 1149-1158
    • Sever, P.S.1    Dahlöf, B.2    Poulter, N.R.3
  • 93
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
    • Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
    • (1995) N Engl J Med , vol.333 , pp. 1301-1307
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3
  • 94
    • 0037840242 scopus 로고    scopus 로고
    • MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial
    • Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial. Lancet 2003;361:2005-2016.
    • (2003) Lancet , vol.361 , pp. 2005-2016
    • Collins, R.1    Armitage, J.2    Parish, S.3
  • 95
    • 78751640788 scopus 로고    scopus 로고
    • Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk
    • Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153: 800-808.
    • (2010) Ann Intern Med , vol.153 , pp. 800-808
    • Jafri, H.1    Alsheikh-Ali, A.A.2    Karas, R.H.3
  • 96
    • 84877730804 scopus 로고    scopus 로고
    • How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol
    • Lim S, Park YM, Sakuma I, et al. How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol 2013;166:8-14.
    • (2013) Int J Cardiol , vol.166 , pp. 8-14
    • Lim, S.1    Park, Y.M.2    Sakuma, I.3
  • 97
    • 84899970979 scopus 로고    scopus 로고
    • Atherogenic dyslipidemia and residual cardiovascular risk in statintreated patients
    • Sirimarco G, Labreuche J, Bruckert E, et al. Atherogenic dyslipidemia and residual cardiovascular risk in statintreated patients. Stroke 2014;45:1429-1436.
    • (2014) Stroke , vol.45 , pp. 1429-1436
    • Sirimarco, G.1    Labreuche, J.2    Bruckert, E.3
  • 98
    • 33846464226 scopus 로고    scopus 로고
    • Safety and efficacy of statins in Asians
    • Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-414.
    • (2007) Am J Cardiol , vol.99 , pp. 410-414
    • Liao, J.K.1
  • 99
    • 33748952489 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial
    • Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006;368:1155-1163.
    • (2006) Lancet , vol.368 , pp. 1155-1163
    • Nakamura, H.1    Arakawa, K.2    Itakura, H.3
  • 100
    • 80053338005 scopus 로고    scopus 로고
    • Ethnic variations in lipid-lowering in response to a statin (EVIREST): A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
    • Chapman N, Chang CL, Caulfield M, et al. Ethnic variations in lipid-lowering in response to a statin (EVIREST): A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis 2011;21:150-157.
    • (2011) Ethn Dis , vol.21 , pp. 150-157
    • Chapman, N.1    Chang, C.L.2    Caulfield, M.3
  • 101
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials
    • Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Baigent, C.1    Blackwell, L.2    Emberson, J.3
  • 102
    • 84930670749 scopus 로고    scopus 로고
    • Lack of effect of lowering LDL cholesterol on cancer: Metaanalysis of individual data from 175,000 people in 27 randomised trials of statin therapy
    • Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: Metaanalysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012;7: e29849.
    • (2012) PLoS One , vol.7 , pp. e29849
    • Emberson, J.R.1    Kearney, P.M.2    Blackwell, L.3
  • 103
    • 85027957106 scopus 로고    scopus 로고
    • Lipid-lowering therapies, glucose control and incident diabetes: Evidence, mechanisms and clinical implications
    • Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incident diabetes: Evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther 2014;28: 361-377.
    • (2014) Cardiovasc Drugs Ther , vol.28 , pp. 361-377
    • Zafrir, B.1    Jain, M.2
  • 104
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
    • Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3
  • 105
    • 84892187236 scopus 로고    scopus 로고
    • Diabetogenic effect of statins: A double-edged sword?
    • Yoon JS, Lee HW. Diabetogenic effect of statins: a double-edged sword? Diabetes Metab J 2013;37:415-422.
    • (2013) Diabetes Metab J , vol.37 , pp. 415-422
    • Yoon, J.S.1    Lee, H.W.2
  • 106
    • 27444443876 scopus 로고    scopus 로고
    • Diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung, and blood institute scientific statement
    • Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
    • (2005) Circulation , vol.112 , pp. 2735-2752
    • Grundy, S.M.1    Cleeman, J.I.2    Daniels, S.R.3
  • 107
    • 84892649479 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2014
    • American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1): S14-S80.
    • (2014) Diabetes Care , vol.37 , pp. S14-S80
  • 108
    • 56249123656 scopus 로고    scopus 로고
    • The residual risk reduction initiative: A call to action to reduce residual vascular risk in dyslipidaemic patient
    • Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008;5:319-335.
    • (2008) Diab Vasc Dis Res , vol.5 , pp. 319-335
    • Fruchart, J.C.1    Sacks, F.M.2    Hermans, M.P.3
  • 109
    • 33749536035 scopus 로고    scopus 로고
    • Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins
    • Tenenbaum A, Fisman EZ, Motro M, et al. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins. Cardiovasc Diabetol 2006;5:20.
    • (2006) Cardiovasc Diabetol , vol.5 , pp. 20
    • Tenenbaum, A.1    Fisman, E.Z.2    Motro, M.3
  • 110
    • 77952708442 scopus 로고    scopus 로고
    • Effects of fibrates on cardiovascular outcomes: A systematic review and metaanalysis
    • Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: A systematic review and metaanalysis. Lancet 2010;375:1875-1884.
    • (2010) Lancet , vol.375 , pp. 1875-1884
    • Jun, M.1    Foote, C.2    Lv, J.3
  • 111
    • 0032506273 scopus 로고    scopus 로고
    • Mechanism of action of fibrates on lipid and lipoprotein metabolism
    • Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093.
    • (1998) Circulation , vol.98 , pp. 2088-2093
    • Staels, B.1    Dallongeville, J.2    Auwerx, J.3
  • 112
    • 0342506477 scopus 로고    scopus 로고
    • Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group
    • Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-2143.
    • (1997) Circulation , vol.96 , pp. 2137-2143
    • Frick, M.H.1    Syvanne, M.2    Nieminen, M.S.3
  • 113
    • 84867235189 scopus 로고    scopus 로고
    • Fibrates are an essential part of modern anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidemia and residual risk reduction
    • Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012;11:125.
    • (2012) Cardiovasc Diabetol , vol.11 , pp. 125
    • Tenenbaum, A.1    Fisman, E.Z.2
  • 114
    • 64749095070 scopus 로고    scopus 로고
    • Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    • Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-498.
    • (2009) Diabetes Care , vol.32 , pp. 493-498
    • Scott, R.1    O'Brien, R.2    Fulcher, G.3
  • 115
    • 19344375593 scopus 로고    scopus 로고
    • Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
    • Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165:1154-1160.
    • (2005) Arch Intern Med , vol.165 , pp. 1154-1160
    • Tenenbaum, A.1    Motro, M.2    Fisman, E.Z.3
  • 116
    • 82855161011 scopus 로고    scopus 로고
    • Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: The case for residual risk reduction after statin treatment
    • Athyros VG, Tziomalos K, Karagiannis A, et al. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: The case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011;5:24-34.
    • (2011) Open Cardiovasc Med J , vol.5 , pp. 24-34
    • Athyros, V.G.1    Tziomalos, K.2    Karagiannis, A.3
  • 117
    • 27744605739 scopus 로고    scopus 로고
    • Pharmacokinetic interactions between statins and fibrates
    • Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96:44K-49K.
    • (2005) Am J Cardiol , vol.96 , pp. 44K-49K
    • Corsini, A.1    Bellosta, S.2    Davidson, M.H.3
  • 118
    • 84873249294 scopus 로고    scopus 로고
    • Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: Contradictions between the two main therapeutic pathways
    • Laszlo A, Kalabay L, Nemcsik J. Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: Contradictions between the two main therapeutic pathways. BMC Res Notes 2013;6:52.
    • (2013) BMC Res Notes , vol.6 , pp. 52
    • Laszlo, A.1    Kalabay, L.2    Nemcsik, J.3
  • 120
    • 0037626887 scopus 로고    scopus 로고
    • Niacin and cholesterol: Role in cardiovascular disease (review)
    • Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: Role in cardiovascular disease (review). J Nutr Biochem 2003;14:298-305.
    • (2003) J Nutr Biochem , vol.14 , pp. 298-305
    • Ganji, S.H.1    Kamanna, V.S.2    Kashyap, M.L.3
  • 121
    • 70350516769 scopus 로고    scopus 로고
    • Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study
    • Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-1794.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 1787-1794
    • Lee, J.M.1    Robson, M.D.2    Yu, L.M.3
  • 122
    • 77953121328 scopus 로고    scopus 로고
    • The ARBITER 6-HALTS trial (Arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration
    • Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-2726.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2721-2726
    • Villines, T.C.1    Stanek, E.J.2    Devine, P.J.3
  • 123
    • 0016630250 scopus 로고
    • Clofibrate and niacin in coronary heart disease
    • Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
    • (1975) JAMA , vol.231 , pp. 360-381
  • 124
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • Boden, W.E.1    Probstfield, J.L.2    Anderson, T.3
  • 125
    • 0035969564 scopus 로고    scopus 로고
    • Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    • Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345: 1583-1592.
    • (2001) N Engl J Med , vol.345 , pp. 1583-1592
    • Brown, B.G.1    Zhao, X.Q.2    Chait, A.3
  • 126
    • 0025183769 scopus 로고
    • Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
    • Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
    • (1990) N Engl J Med , vol.323 , pp. 1289-1298
    • Brown, G.1    Albers, J.J.2    Fisher, L.D.3
  • 127
    • 77952397461 scopus 로고    scopus 로고
    • Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    • Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-361.
    • (2010) Atherosclerosis , vol.210 , pp. 353-361
    • Bruckert, E.1    Labreuche, J.2    Amarenco, P.3
  • 128
    • 0023001772 scopus 로고
    • Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
    • Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
    • (1986) J Am Coll Cardiol , vol.8 , pp. 1245-1255
    • Canner, P.L.1    Berge, K.G.2    Wenger, N.K.3
  • 129
    • 0034644442 scopus 로고    scopus 로고
    • Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial
    • Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-1270.
    • (2000) JAMA , vol.284 , pp. 1263-1270
    • Elam, M.B.1    Hunninghake, D.B.2    Davis, K.B.3
  • 130
    • 0037158150 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
    • Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-1576.
    • (2002) Arch Intern Med , vol.162 , pp. 1568-1576
    • Grundy, S.M.1    Vega, G.L.2    McGovern, M.E.3
  • 131
    • 84904252744 scopus 로고    scopus 로고
    • Effects of extended-release niacin with laropiprant in high-risk patients
    • HPS2-THRIVE Collaborative Group, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371: 203-212.
    • (2014) N Engl J Med , vol.371 , pp. 203-212
    • Haynes, R.1    Hopewell, J.C.2
  • 132
    • 42149136762 scopus 로고    scopus 로고
    • Effects of niacin on glucose control in patients with dyslipidemia
    • Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470-478.
    • (2008) Mayo Clin Proc , vol.83 , pp. 470-478
    • Goldberg, R.B.1    Jacobson, T.A.2
  • 133
    • 84862107330 scopus 로고    scopus 로고
    • Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial
    • Guyton JR, Fazio S, Adewale AJ, et al. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care 2012;35: 857-860.
    • (2012) Diabetes Care , vol.35 , pp. 857-860
    • Guyton, J.R.1    Fazio, S.2    Adewale, A.J.3
  • 134
    • 84875540714 scopus 로고    scopus 로고
    • Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose
    • Sazonov V, Maccubbin D, Sisk CM, et al. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract 2013;67:297-302.
    • (2013) Int J Clin Pract , vol.67 , pp. 297-302
    • Sazonov, V.1    MacCubbin, D.2    Sisk, C.M.3
  • 136
    • 84904265666 scopus 로고    scopus 로고
    • Safety profile of extended-release niacin in the AIMHIGH trial
    • Anderson TJ, Boden WE, Desvigne-Nickens P, et al. Safety profile of extended-release niacin in the AIMHIGH trial. N Engl J Med 2014;371:288-290.
    • (2014) N Engl J Med , vol.371 , pp. 288-290
    • Anderson, T.J.1    Boden, W.E.2    Desvigne-Nickens, P.3
  • 137
    • 0037137299 scopus 로고    scopus 로고
    • Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
    • Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757.
    • (2002) Circulation , vol.106 , pp. 2747-2757
    • Kris-Etherton, P.M.1    Harris, W.S.2    Appel, L.J.3
  • 138
    • 0024363690 scopus 로고
    • Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART)
    • Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989;2:757-761.
    • (1989) Lancet , vol.2 , pp. 757-761
    • Burr, M.L.1    Fehily, A.M.2    Gilbert, J.F.3
  • 139
    • 0345109256 scopus 로고    scopus 로고
    • Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: Results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico
    • GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354: 447-455.
    • (1999) Lancet , vol.354 , pp. 447-455
  • 140
    • 33947583493 scopus 로고    scopus 로고
    • Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis
    • Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007;369: 1090-1098.
    • (2007) Lancet , vol.369 , pp. 1090-1098
    • Yokoyama, M.1    Origasa, H.2    Matsuzaki, M.3
  • 141
    • 84866124338 scopus 로고    scopus 로고
    • Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
    • Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984-992.
    • (2012) Am J Cardiol , vol.110 , pp. 984-992
    • Ballantyne, C.M.1    Bays, H.E.2    Kastelein, J.J.3
  • 142
    • 80051784104 scopus 로고    scopus 로고
    • Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)
    • Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-690.
    • (2011) Am J Cardiol , vol.108 , pp. 682-690
    • Bays, H.E.1    Ballantyne, C.M.2    Kastelein, J.J.3
  • 143
    • 78549233384 scopus 로고    scopus 로고
    • N-3 Fatty acids and cardiovascular events after myocardial infarction
    • Kromhout D, Giltay EJ, Geleijnse JM, et al. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-2026.
    • (2010) N Engl J Med , vol.363 , pp. 2015-2026
    • Kromhout, D.1    Giltay, E.J.2    Geleijnse, J.M.3
  • 144
    • 84864219466 scopus 로고    scopus 로고
    • N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
    • Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-318.
    • (2012) N Engl J Med , vol.367 , pp. 309-318
    • Bosch, J.1    Gerstein, H.C.2    Dagenais, G.R.3
  • 145
    • 84877624255 scopus 로고    scopus 로고
    • N-3 fatty acids in patients with multiple cardiovascular risk factors
    • Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-1808.
    • (2013) N Engl J Med , vol.368 , pp. 1800-1808
    • Roncaglioni, M.C.1    Tombesi, M.2    Avanzini, F.3
  • 146
    • 33645566760 scopus 로고    scopus 로고
    • Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review
    • Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review. BMJ 2006;332: 752-760.
    • (2006) BMJ , vol.332 , pp. 752-760
    • Hooper, L.1    Thompson, R.L.2    Harrison, R.A.3
  • 147
    • 78650169331 scopus 로고    scopus 로고
    • OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction
    • Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-2159.
    • (2010) Circulation , vol.122 , pp. 2152-2159
    • Rauch, B.1    Schiele, R.2    Schneider, S.3
  • 148
    • 84871014821 scopus 로고    scopus 로고
    • Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 fatty acid ethyl esters
    • Athyros VG, Mikhailidis DP. Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 fatty acid ethyl esters. Open Cardiovasc Med J 2012;6:122-125.
    • (2012) Open Cardiovasc Med J , vol.6 , pp. 122-125
    • Athyros, V.G.1    Mikhailidis, D.P.2
  • 149
    • 34548319692 scopus 로고    scopus 로고
    • Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebocontrolled study
    • Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebocontrolled study. Clin Ther 2007;29:1354-1367.
    • (2007) Clin Ther , vol.29 , pp. 1354-1367
    • Davidson, M.H.1    Stein, E.A.2    Bays, H.E.3
  • 150
    • 84884355278 scopus 로고    scopus 로고
    • A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)
    • Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther 2013;35:1400-1411.
    • (2013) Clin Ther , vol.35 , pp. 1400-1411
    • Maki, K.C.1    Orloff, D.G.2    Nicholls, S.J.3
  • 151
    • 0030862755 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4
    • Singh RB, Niaz MA, Sharma JP, et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997;11:485-491.
    • (1997) Cardiovasc Drugs Ther , vol.11 , pp. 485-491
    • Singh, R.B.1    Niaz, M.A.2    Sharma, J.P.3
  • 152
    • 49749128376 scopus 로고    scopus 로고
    • Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
    • Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008;200:135-140.
    • (2008) Atherosclerosis , vol.200 , pp. 135-140
    • Saito, Y.1    Yokoyama, M.2    Origasa, H.3
  • 153
    • 84872416659 scopus 로고    scopus 로고
    • Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction:Aretrospective, matched-cohort study
    • Poole CD, Halcox JP, Jenkins-Jones S, et al. Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction:Aretrospective, matched-cohort study. Clin Ther 2013;35:40-51.
    • (2013) Clin Ther , vol.35 , pp. 40-51
    • Poole, C.D.1    Halcox, J.P.2    Jenkins-Jones, S.3
  • 154
    • 33645007540 scopus 로고    scopus 로고
    • Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I
    • Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006;113:195-202.
    • (2006) Circulation , vol.113 , pp. 195-202
    • Iso, H.1    Kobayashi, M.2    Ishihara, J.3
  • 155
    • 36348975228 scopus 로고    scopus 로고
    • Effects of torcetrapib in patients at high risk for coronary events
    • Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
    • (2007) N Engl J Med , vol.357 , pp. 2109-2122
    • Barter, P.J.1    Caulfield, M.2    Eriksson, M.3
  • 156
    • 84870045994 scopus 로고    scopus 로고
    • Effects of dalcetrapib in patients with a recent acute coronary syndrome
    • Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099.
    • (2012) N Engl J Med , vol.367 , pp. 2089-2099
    • Schwartz, G.G.1    Olsson, A.G.2    Abt, M.3
  • 157
    • 84920525718 scopus 로고    scopus 로고
    • Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians
    • 2047487314528461. First Published March 21, 2014
    • Rashid S, Sniderman A, Melone M, et al. Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. Eur J Prev Cardiol 2014;2047487314528461. First Published March 21, 2014.
    • (2014) Eur J Prev Cardiol
    • Rashid, S.1    Sniderman, A.2    Melone, M.3
  • 158
    • 79959746706 scopus 로고    scopus 로고
    • The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
    • Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
    • (2011) Lancet , vol.377 , pp. 2181-2192
    • Baigent, C.1    Landray, M.J.2    Reith, C.3
  • 159
    • 50949102416 scopus 로고    scopus 로고
    • Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    • Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-832.
    • (2008) Am Heart J , vol.156 , pp. 826-832
    • Cannon, C.P.1    Giugliano, R.P.2    Blazing, M.A.3
  • 160
    • 41649107358 scopus 로고    scopus 로고
    • Simvastatin with or without ezetimibe in familial hypercholesterolemia
    • Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443.
    • (2008) N Engl J Med , vol.358 , pp. 1431-1443
    • Kastelein, J.J.1    Akdim, F.2    Stroes, E.S.3
  • 161
    • 44349126634 scopus 로고    scopus 로고
    • The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1
    • Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008;7:508-519.
    • (2008) Cell Metab , vol.7 , pp. 508-519
    • Ge, L.1    Wang, J.2    Qi, W.3
  • 162
    • 84905040766 scopus 로고    scopus 로고
    • Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
    • Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014;168: 205-212.
    • (2014) Am Heart J , vol.168 , pp. 205-212
    • Blazing, M.A.1    Giugliano, R.P.2    Cannon, C.P.3
  • 163
    • 84858638369 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
    • Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118.
    • (2012) N Engl J Med , vol.366 , pp. 1108-1118
    • Stein, E.A.1    Mellis, S.2    Yancopoulos, G.D.3
  • 164
    • 84863494422 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial
    • Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012;380:29-36.
    • (2012) Lancet , vol.380 , pp. 29-36
    • Stein, E.A.1    Gipe, D.2    Bergeron, J.3
  • 165
    • 84871326497 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial
    • Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 2012;308:1-10.
    • (2012) JAMA , vol.308 , pp. 1-10
    • Sullivan, D.1    Olsson, A.G.2    Scott, R.3
  • 166
    • 84869220345 scopus 로고    scopus 로고
    • Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial
    • Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-2417.
    • (2012) Circulation , vol.126 , pp. 2408-2417
    • Raal, F.1    Scott, R.2    Somaratne, R.3
  • 167
    • 84871995815 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2013
    • American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl 1: S11-S66.
    • (2013) Diabetes Care , vol.36 , pp. S11-S66
  • 168
    • 84860144206 scopus 로고    scopus 로고
    • American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis
    • Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 2012;18(Suppl 1):1-78.
    • (2012) Endocr Pract , vol.18 , pp. 1-78
    • Jellinger, P.S.1    Smith, D.A.2    Mehta, A.E.3
  • 169
    • 84880422112 scopus 로고    scopus 로고
    • Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial
    • Guasch-Ferre M, Bullo M, Martinez-Gonzalez MA, et al. Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial. BMC Med 2013; 11:164.
    • (2013) BMC Med , vol.11 , pp. 164
    • Guasch-Ferre, M.1    Bullo, M.2    Martinez-Gonzalez, M.A.3
  • 170
    • 84902576469 scopus 로고    scopus 로고
    • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;63:2889-2934.
    • (2013) J Am Coll Cardiol , vol.63 , pp. 2889-2934
    • Stone, N.J.1    Robinson, J.2    Lichtenstein, A.H.3
  • 171
    • 84921441124 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists. Member alert regarding new guidelines. 2013. Available at https://www.aace.com/sites/all/files/Member-Alert-Re-Guidelines-112113.pdf
    • (2013) Member Alert Regarding New Guidelines
  • 172
    • 84898950294 scopus 로고    scopus 로고
    • The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011
    • Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-968.
    • (2014) Eur Heart J , vol.35 , pp. 960-968
    • Ray, K.K.1    Kastelein, J.J.2    Boekholdt, S.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.